Henlius weighs HLX43 licensing deal

Henlius Biotech is in talks with Johnson & Johnson and Roche to license rights to HLX43, a mid-stage cancer drug, according to people familiar with the matter. A deal could involve substantial upfront and milestone payments. Henlius has denied the report, though its shares rose after it emerged.